CYP3A抑制剂对quizartinib及其活性代谢物药代动力学的影响
结果显示强效抑制剂酮康唑使quizartinib暴露约增2倍,中效氟康唑影响较小,提示仅与强效CYP3A抑制剂联用需减量。
要点
- 强效CYP3A抑制剂酮康唑使quizartinib稳态Cmax和AUC约增加2倍。
- 中效CYP3A抑制剂氟康唑对quizartinib暴露影响较小。
- 与强效CYP3A抑制剂联用时应减少quizartinib剂量。
核心结论
- 与强效CYP3A抑制剂联用时应降低quizartinib剂量,与中效或弱效抑制剂联用则无需减量。
主要发现
- 合用酮康唑时quizartinib的Cmax几何均值比为117%(90%CI 105%, 130%),AUC0-inf几何均值比为194%(90%CI 169%, 223%)。
- 稳态模拟显示合用酮康唑时quizartinib稳态Cmax和AUC均约增加2倍。
- 合用氟康唑时quizartinib的Cmax几何均值比为111%(90%CI 100%, 124%),AUC0-inf几何均值比为120%(90%CI 104%, 138%)。
- 5.4%的受试者发生quizartinib相关不良事件,未发生严重不良事件或死亡。
关键数值与推荐
- 强效CYP3A抑制剂(如酮康唑)与quizartinib联用需减量。
- 中效或弱效CYP3A抑制剂与quizartinib联用无需减量。
临床怎么用
- 临床使用quizartinib时应评估合并用药的CYP3A抑制强度,强效抑制剂联用需按推荐减量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia. This drug-drug interaction study assessed the pharmacokinetics (PK) of quizartinib when coadministered with strong or moderate cytochrome P450 3A (CYP3A) inhibitors. METHODS: In this parallel-group study, subjects were randomised to receive: (i) quizartinib + ketoconazole; (ii) quizartinib + fluconazole; or (iii) quizartinib alone. On Days 1-28, subjects received ketoconazole 200 mg or fluconazole 200 mg twice daily, and on Day 8, all subjects received a single 30-mg quizartinib dose. Blood samples were collected for PK analyses, steady-state PK parameters were simulated by superpositioning, and safety was assessed. RESULTS: Ninety-three healthy subjects were randomised; 86 completed the study. When administered with ketoconazole, geometric mean ratios (90% confidence interval) for quizartinib maximum observed plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) from time 0 extrapolated to infinity were 117% (105%, 130%) and 194% (169%, 223%), respectively, vs quizartinib alone. Steady-state PK simulation demonstrated ~2-fold increase of both steady-state Cmax and AUC from time 0 to the end of the dosing interval when quizartinib was administered with ketoconazole due to accumulation of quizartinib at steady state. When administered with fluconazole, geometric mean ratios (90% confidence interval) for quizartinib Cmax and AUC from time 0 extrapolated to infinity were 111% (100%, 124%) and 120% (104%, 138%), respectively, vs quizartinib alone. Overall, 5.4% of subjects experienced quizartinib-related adverse events; no serious adverse events or deaths occurred. CONCLUSIONS: These results suggest reducing the dose of quizartinib when coadministered with a strong CYP3A inhibitor, but not with a moderate or weak CYP3A inhibitor. This dose reduction was implemented in phase 3 evaluation of quizartinib.
引用
- Li J, Kankam M, Trone D, et al. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Br J Clin Pharmacol. 2019. PMID: 31173645. doi:10.1111/bcp.14022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。